Attorney General Hanaway Orders Eli Lilly To Halt Unlawful Prescription Pricing Conditions

On July 2, 2026, Eli Lilly and Company cut University of Missouri Health Care (MU Health Care) off from 340B pricing after MU Health Care refused to comply with Lilly's new data-submission policy. That policy requires 340B-participating hospitals to submit detailed claims data for every dispensation of any Lilly product, regardless of care setting, as a condition of accessing federally mandated 340B discounted pricing. To avoid continued financial losses and patient harm, MU Health Care agreed to temporarily provide the demanded data while reserving its legal rights. Missouri Attorney General Catherine Hanaway issued a cease-and-desist letter to Lilly directing the manufacturer to immediately end the data-submission requirement as a condition of 340B pricing in Missouri and to stop using any claims data already collected under the policy. The Attorney General's letter characterizes Lilly's conduct as misleading consumers and covered entities by representing that 340B prices are available while simultaneously withholding those prices from hospitals that decline to provide the data. The letter further characterizes the policy as an abuse of market power that imposes unlawful conditions on Missouri healthcare providers in violation of federal intent and Missouri law. Failure to comply with the cease-and-desist letter may result in an enforcement action under the Missouri Merchandising Practices Act. The Attorney General specifically cited the effect on rural Missouri hospitals that depend on the 340B program to operate emergency rooms, maintain oncology services, and provide medications to low-income and uninsured patients.